Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Share this article

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part of a larger project, the Walloon Cell Therapy Platform. “Our objective is to become a champion of bone regenerative medicine with international aspirations.” said Enrico Bastianelli, CEO of Bone Therapeutics. After the successful initial public offering on Euronext Brussels and Paris, the company has established its US based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts. This is the first milestone in the initiation of Bone Therapeutics’ clinical trials in the US. “This further strengthens the international reach of our innovative pipeline of bone cell therapy products” further explains Bastianelli.

Bone Therapeutics is a bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention and is investigating therapeutic approaches to address conditions as spinal fusion, osteonecrosis and osteoporosis. The current standard-of-care in this field often involves major surgeries with long recovery times. To overcome this, Bone Therapeutics develops innovative regenerative products containing bone-forming cells (osteoblasts), administrable via a minimally invasive procedure. Bone Therapeutics’ autologous product PREOB® is currently in two Phase III studies for the treatment of osteonecrosis and non-union fractures and in Phase II development for the treatment of severe osteoporosis. Its allogeneic cell therapy product ALLOB® is being tested in Phase II for delayed-union fractures and for use in spine fusion surgery.